DNLI research · 13F holders by reporting quarter
Denali Therapeutics Inc. (DNLI): 13F holders, 2025Q4
The largest share positions in DNLI that the managers Kresmion follows reported on Form 13F for 2025Q4, as filed. The current quarter, the company's SEC filings and its recent events are on the DNLI research page.
DNLI positions held by the managers we follow (2025Q4)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P. FundCUSIP 24823R105 · 2025Q4 | $28.1M | 0.04% | -32.5% |
| CITADEL ADVISORS LLC FundCUSIP 24823R105 · 2025Q4 | $12.9M | 0.01% | -91.3% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 24823R105 · 2025Q4 | $7.1M | 0.01% | +61.5% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 24823R105 · 2025Q4 | $6.1M | 0.00% | -71.7% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 24823R105 · 2025Q4 | $177K | 0.00% | -82.1% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.